Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zai Lab Limited
  6. Company
    ZLAB   US98887Q1040

ZAI LAB LIMITED

(ZLAB)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
38.84 USD   +3.77%
10:25aZai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commercialize Tivdak
MT
08:41aZai Lab : Corporate Presentation
PU
08:11aZai Lab Ltd : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Number of employees : 1 951 people.
Sales per Business
20202021Delta
Medicines for Oncology, Autoimmune Disorders, Infectious Diseases and Neurological Disorders48.96100%144.31100% +194.77%
USD in Million
Sales per region
20202021Delta
Greater China and United States48.96100%144.31100% +194.77%
USD in Million
Managers
Name Title Age Since
Ying Du Chairman & Chief Executive Officer 56 2014
Billy Cho Chief Financial Officer 43 2018
Ning Xu Executive VP & Head-Clinical Operations 56 2014
James Yan Chief Operating Officer-Research & Development 57 2020
Joshua Smiley Chief Operating Officer 51 2022
Ann E. Beasley Chief Compliance Officer - 2020
Ron Aldridge Executive Director-Investor Relations - -
F. Ty Edmondson Joint Secretary & Chief Legal Officer 55 2022
Li Ni Ou Yang Joint Secretary - 2022
Jonathan Wang Senior Vice President & Head-Business Development 39 2014
Members of the board
Name Title Age Since
Ying Du Chairman & Chief Executive Officer 56 2014
John D. Diekman, Dr. Independent Director 78 2017
Peter Wirth Independent Director 70 2020
Kai-Xian Chen, Dr. Independent Director 75 2018
William Lis Independent Director 57 2018
Leon O. Moulder, Dr. Independent Director 63 2019
Scott W. Morrison Independent Director 63 2021
Richard B. Gaynor, Dr. Independent Director 71 2021
Wing Yu Leung Director 51 2014
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 957,035,440 955,585,059 99.8% 398,080 0.0% 99.8%
Shareholders
NameEquities%
Invesco Advisers, Inc. 8,173,817 8.35%
Viking Global Investors LP 3,299,598 3.37%
Fidelity Management & Research Co. LLC 2,432,679 2.48%
Ecor1 Capital LLC 2,431,885 2.48%
Segantii Capital Management Ltd. 2,241,274 2.29%
Janus Henderson Investors US LLC 1,913,144 1.95%
Federated Global Investment Management Corp. 1,872,000 1.91%
The Vanguard Group, Inc. 1,742,846 1.78%
BAMCO, Inc. 1,728,961 1.77%
Genesis Investment Management LLP 1,610,174 1.64%
Company contact information
Zai Lab Ltd.
Jinchuang Plaza
Building 1, 4/F
No. 4560 Jinke Road, Pudong District
Shanghai 201210

Phone : +86.21.6163.2588
Fax : +86.21.6163.2570
Web : http://www.zailaboratory.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Zai Lab Limited